title: [Expression and clinical significance of PTPN14 in cholangiocarcinoma].
abstract: OBJECTIVE
  To investigate the expression level of protein tyrosine phosphatase non-receptor type 14 (PTPN14), and analyze the relationship between PTPN14 and clinical pathological features and prognosis of patients with cholangiocarcinoma.
  
  
  METHODS
  Expression of PTPN14 protein was detected by immunohistochemistry (IHC) in 57 cholangiocarcinoma tissues and corresponding adjacent normal tissues. The relationship between PTPN14 protein level and the clinical-pathological features of cholangiocarcinoma was analyzed using IBM SPSS 20.0 statistical software. The relationship between PTPN14 protein expression and 5-year overall survival of cholangiocarcinoma patients was investigated by survival curves.
  
  
  RESULTS
  IHC revealed that positive rates of PTPN14 protein were 49.1% and 75.4% in cholangiocarcinoma tissues and adjacent tissues, respectively. The expression of PTPN14 protein was significantly associated with TNM I, II, and differentiation degree of cholangiocarcinoma patients, but not significantly associated with age and gender of cholangiocarcinoma patients. The 5-year overall survival rate was higher in the PTPN14-positive patients than the PTPN14-negative ones.
  
  
  CONCLUSIONS
  PTPN14 was down-regulated in cholangiocarcinoma, and negatively correlated with better clinical-pathological features and 5-year overall survival rate of cholangiocarcinoma.
authors.affiliation: Department of Oncology, First Affiliated Hospital, Xi'an Jiaotong University, Xi'an 710061, China.
authors.forename: Lijuan
authors.initials: L
authors.lastname: Wang
authors.affiliation: Department of Immunology, School of Basic Medicine, Fourth Military Medical University, Xi'an 710032, China.
authors.forename: Wenjin
authors.initials: W
authors.lastname: Xi
authors.affiliation: Department of Immunology, School of Basic Medicine, Fourth Military Medical University, Xi'an 710032, China.
authors.forename: Guoxu
authors.initials: G
authors.lastname: Zheng
authors.affiliation: Department of Oncology, First Affiliated Hospital, Xi'an Jiaotong University, Xi'an 710061, China.
authors.forename: Congya
authors.initials: C
authors.lastname: Zhou
authors.affiliation: Department of Oncology, First Affiliated Hospital, Xi'an Jiaotong University, Xi'an 710061, China.
authors.forename: Guihua
authors.initials: G
authors.lastname: Jin
authors.affiliation: Department of Oncology, First Affiliated Hospital, Xi'an Jiaotong University, Xi'an 710061, China.
authors.forename: Chenchen
authors.initials: C
authors.lastname: He
authors.affiliation: Department of Oncology, First Affiliated Hospital, Xi'an Jiaotong University, Xi'an 710061, China.
authors.forename: Mengjiao
authors.initials: M
authors.lastname: Cai
authors.affiliation: Department of Oncology, First Affiliated Hospital, Xi'an Jiaotong University, Xi'an 710061, China.
authors.forename: Qing
authors.initials: Q
authors.lastname: Zhu
mesh_terms: D000328:Adult; D000368:Aged; D001650:Bile Duct Neoplasms / Q000401:mortality / Q000473:pathology*; D018281:Cholangiocarcinoma / Q000401:mortality / Q000473:pathology*; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D008875:Middle Aged; D054558:Protein Tyrosine Phosphatases, Non-Receptor / Q000032:analysis / Q000502:physiology*; D015996:Survival Rate
chemical_list: C093261:PTPN14 protein, human; D054558:Protein Tyrosine Phosphatases, Non-Receptor